TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2662837
Drug: Fenoterol syrup
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol syrup (0.25 mg/kg daily dosage)
Study: 23184737
Drug: Inhaled Fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Fluticasone Furoate (FF) 2000 μg via DISKHALER(®)
Study: 23184737
Drug: Inhaled Fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Fluticasone Propionate (FP) 1000 μg via DISKHALER(®)
Study: 18474077
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) at a maximum dosage of 1500 mg daily
Study: 10720048
Drug: Flutamide, testolactone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide, testolactone, reduced hydrocortisone dose (average of 8.7 +/- 0.6 mg/m2 x day), and fludrocortisone
Study: 22445512
Drug: Rimonabant (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimonabant (20 mg/d) for 12 weeks
Study: 15632467
Drug: Ibandronate (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate (bolus intravenous injection)
Study: 9064947
Drug: 24 h
Normalized name: Immune 24 Hour +
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 h NTG-infusion (group A; 0-24 h saline infusion followed by a 24 h NTG-infusion; n = 16)
Study: 9064947
Drug: 48 h
Normalized name: DIAZOLIDINYL UREA 446 ug in 48 h / CLIOQUINOL 77 ug in 48 h / CHLORQUINALDOL 77 ug in 48 h / TIXOCORTOL PIVALATE 2 ug in 48 h / GOLD SODIUM THIOSULFATE 23 ug in 48 h / IMIDUREA 486 ug in 48 h / BUDESONIDE 0.8 ug in 48 h / HYDROCORTISONE BUTYRATE 16 ug in 48 h / 2-MERCAPTOBENZOTHIAZOLE 61 ug in 48 h / BACITRACIN 486 ug in 48 h / PARTHENOLIDE 2 ug in 48 h / DISPERSE BLUE 106 41 ug in 48 h / BRONOPOL 203 ug in 48 h CUTANEOUS PATCH [T.R.U.E. Test Panel 3.3]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 48 h NTG-infusion (group B; 0-48 h of NTG-infusion; n = 16)
Study: 9064947
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (control for group A)
Study: 9064947
Drug: NTG-infusion (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTG-infusion (both groups)
Study: 1433584
Drug: Random medical
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Random medical treatment
Study: 1433584
Drug: Sideline medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sideline medical treatment
Study: 6398121
Drug: R 14
Normalized name: SR 140333
DrugBank: SR 140333 (DB05790)
Approvals — FDA: no, EMA: no, PMDA: no
Description: R 14 regimen (cyclophosphamide 2 mg/kg/iv, vincristine 0.01 mg/kg/iv, vinblastine 0.1 mg/kg/iv, 5‐fluorouracil 5 mg/kg/iv, methotrexate 0.7 mg/kg/iv, adriamycin 0.5 mg/kg/iv every 21 days)
Study: 6398121
Drug: CMF regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF regimen (cyclophosphamide 100 mg/m2/po, methotrexate 40 mg/m2/iv, 5‐fluorouracil 600 mg/m2/iv)
Study: 30853809
Drug: Individual computer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual computer magnanimous therapy (ic‐mt)
Study: 30853809
Drug: Group computer
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group computer magnanimous therapy (gc‐mt)
Study: 27362402
Drug: Imported histamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imported histamine 1 mg/mL
Study: 27362402
Drug: Locally-prepared histamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locally-prepared histamine 1 mg/mL
Study: 27362402
Drug: Locally-prepared histamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locally-prepared histamine 5 mg/mL
Study: 27362402
Drug: Locally-prepared histamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locally-prepared histamine 10 mg/mL
Study: 18343177
Drug: L-arginine capsules
DrugBank: L-arginine (DB17289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine capsules
Study: 15963077
Drug: Rifaximin 800
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin 800 mg/day
Study: 12647599
Drug: Chlorthalidone (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (12.5 to 25 mg/day; n = 15,255)
Study: 12647599
Drug: Amlodipine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (2.5 to 10 mg/day; n = 9,048)
Study: 12647599
Drug: Lisinopril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (10 to 40 mg; n = 9,054)
Study: 10497444
Drug: Theophylline (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (5-20 micrograms/ml)
Study: 10497444
Drug: Theophylline (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (10-20 micrograms/ml)
Study: 30907159
Drug: Web-based physiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based physiotherapy intervention (twice-weekly sessions)
Study: 27803231
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose dual-antibiotic impregnated cement
Study: 27803231
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose single-antibiotic impregnated cement
Study: 24848642
Drug: L‐buthionine sulfoximine
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐buthionine sulfoximine (L‐BSO, 20 μM)
Study: 17046182
Drug: Immediate discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate discontinuation of hormone therapy (n=35)
Study: 17046182
Drug: Tapered discontinuation
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapered discontinuation of hormone therapy (n=35)
Study: 16390401
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (amBisome) 50 mg daily
Study: 16390401
Drug: Conventional amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional amphotericin B (amB) 15 mg daily
Study: 12926181
Drug: Short-term immunotherapy
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term immunotherapy with TA tree pollen and the immunoadjuvant monophosphoryl Lipid A
Study: 12926181
Drug: Placebo suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo suspension containing 2% tyrosine
Study: 8535656
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of disease‐modifying antirheumatic drugs (DMARDs)
Study: 2650722
Drug: Cisplatin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (100 mg/m2) monthly for up to 5 cycles
Study: 2650722
Drug: Carboplatin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (400 mg/m2) monthly for up to 5 cycles
Study: 882723
Drug: 0.15 mg
Normalized name: iodine 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg isoproterenol sulfate
Study: 30052699
Drug: Weekly self-incentivizing
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly self-incentivizing (n = 44)
Study: 30052699
Drug: Monthly self-incentivizing
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly self-incentivizing (n = 50)
Study: 20512497
Drug: Probiotic intervention
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic intervention with fermented milk prepared with Lactobacillus GG and L. gasseri TMC0356 for 10 weeks during pollen spread
Study: 20512497
Drug: Probiotic intervention
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic intervention with fermented milk prepared with Lactobacillus GG and L. gasseri TMC0356
Study: 19332233
Drug: Baseline serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline serum phosphorus >3.9 mg/dL
Study: 19332233
Drug: Baseline calcium‐phosphorus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline calcium‐phosphorus product >36.8 mg(2)/dL(2)
Study: 16846734
Drug: Gemcitabine 1,250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1,250 mg/m(2) Days 1 and 8 and paclitaxel 175 mg/m(2) as a 3‐h infusion on Day 1 (GP1)
Study: 16846734
Drug: Gemcitabine 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1,000 mg/m(2) Days 1 and 8 and paclitaxel 100 mg/m(2) as a 1‐h infusion on Days 1 and 8 (GP2)
Study: 16846734
Drug: Gemcitabine 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1,000 mg/m(2) Days 1 and 8 and docetaxel 40 mg/m(2) as a 1‐h infusion on Days 1 and 8 (GD)
Study: 12631049
Drug: Carbohydrate-rich drinks
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-rich drinks (2 x 400 ml)
Study: 12631049
Drug: Carbohydrate with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate with peptide drinks (2 x 400 ml)
Study: 3919752
Drug: 0.06 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.06 mg/kg of lormetazepam
Study: 3919752
Drug: 0.03 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03 mg/kg of flunitrazepam
Study: 29446084
Drug: PP1M (50-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: PP1M (50-150 mg-eq)
Study: 22436170
Drug: Ondasetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondasetron 8 mg iv
Study: 22436170
Drug: Haloperidol 5
Normalized name: haloperidol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 5 mg iv
Study: 18955908
Drug: Viewing point-light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viewing point-light dot animations of biological motion (specifics on dosage and duration not available)
Study: 8558750
Drug: Initial bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial bolus dose of 30% rt-PA (41.4 mg) followed by infusion over 60 min
Study: 8558750
Drug: Initial bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial bolus dose of 10% rt-PA (41.4 mg) followed by infusion over 60 min
Study: 6452463
Drug: Erythromycin, 1.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin, 1.5% topical solution (n = 127)
Study: 30170024
Drug: Hydrogels (Level
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogels (Level 1 - syrup, Level 2 - custard, Level 3 - pudding)
Study: 26048602
Drug: Conventional occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional occupational therapy (5 times per week)
Study: 26048602
Drug: Conventional occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional occupational therapy (3 times per week) + differential training-based occupational therapy (2 times per week)
Study: 24565295
Drug: Group HDO
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group HDO (ondansetron 8 mg, dexamethasone 8 mg, haloperidol 2 mg)
Study: 17208898
Drug: ABC/3TC/ZDV (300/150/300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABC/3TC/ZDV (300/150/300 mg) and TDF (300 mg) once daily
Study: 10834422
Drug: Injected liquid
Normalized name: Liquid PedvaxHIB Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injected liquid silicone (6 injections of 0.2 ml)
Study: 9663840
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate 400 mg b.d. plus clarithromycin 500 mg b.d.
Study: 9663840
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.d. plus amoxycillin 1000 mg b.d.
Study: 18758356
Drug: Epidural methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural methylprednisolone 40 mg
Study: 12571466
Drug: Dexamethasone (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.6 mg/kg per day for 4 consecutive days once monthly for 6 months, n = 15)
Study: 12571466
Drug: IVIg (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIg (800 mg/kg intravenously once monthly for 6 months, n = 8)
Study: 10850589
Drug: ATG Fresenius
Normalized name: equine ATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG Fresenius S (9 mg/kg)
Study: 8577016
Drug: Structured lipids
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured lipids (1.0 g/kg per day in part 1, 1.5 g/kg per day in part 2)
Study: 8577016
Drug: Long-chain triglycerides
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-chain triglycerides (LCT) (1.0 g/kg per day in part 1, 1.5 g/kg per day in part 2)
Study: 3155240
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment for the first 10 days of the disease
Study: 3155240
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of steroids
Study: 1210468
Drug: Cyclophosphamide (intraarticular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (intraarticular treatment)
Study: 28522351
Drug: Early supplemental
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early supplemental parenteral nutrition (PN)
Study: 26137564
Drug: High-dose patritumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose patritumab
Study: 26137564
Drug: Low-dose patritumab
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose patritumab
Study: 23314982
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (4,000 IU daily for 5 days)
Study: 23314982
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (optimal medical therapy without vitamin D supplementation)
Study: 21606648
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 3,600 mg/day
Study: 21411701
Drug: Interferon‐α/β receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon‐α/β receptor expression
Study: 27945235
Drug: Pretherapeutical Hb
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pretherapeutical Hb levels >13.5 g/dl
Study: 27945235
Drug: Pretherapeutical Hb
Normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pretherapeutical Hb levels <12.7 g/dl and >14.75 g/dl
Study: 11814373
Drug: Daily supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplementation (Group A, n = 70) - 350 mg ferrous sulfate and 1.5 mg folic acid once daily for 90 to 100 days
Study: 11814373
Drug: Weekly supplementation
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly supplementation (Group B, n = 67) - same dosage as Group A but administered once a week for 14 weeks
Study: 2903057
Drug: Intravenous cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide, methotrexate and 5-fluorouracil
Study: 19195824
Drug: Alumina ceramic-on-ceramic
Normalized name: ALUMINA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alumina ceramic-on-ceramic (CC)
Study: 11880817
Drug: Concurrent strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent strength and endurance training (CC)
Study: 10084558
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose short synacthen test (LDSST) - 1 microg tetracosactrin, ACTH-(1-24)
Study: 10084558
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose short synacthen test (SST) - 250 microg tetracosactrin, ACTH-(1-24)
Study: 2321994
Drug: Topical 0.05%
Normalized name: ingenol topical 0.05% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.05% tretinoin solution applied once a day under tape occlusion or twice a day unoccluded for 4 months
Study: 29252022
Drug: Web-based survey
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based survey administration (e-mail distribution)
Study: 29252022
Drug: In-clinic survey
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-clinic survey administration
Study: 29252022
Drug: Web-based survey
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based survey administration
Study: 23281420
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg intra-articular morphine
Study: 23281420
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg intra-articular morphine
Study: 19337769
Drug: Sugar cane
Normalized name: Sugar cane pollen
DrugBank: Sugarcane (DB10906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar cane policosanols (10 mg/day)
Study: 12913699
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months of neoadjuvant hormone therapy (NHT) with 100 mg cyproterone acetate 3 times daily before surgery
Study: 12913699
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months of neoadjuvant hormone therapy (NHT)
Study: 11064528
Drug: Patients' belief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients' belief in effective treatments and perceived ability to cope
Study: 8829026
Drug: Ketoprofen gel
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen gel (2.5% w/w)
Study: 8829026
Drug: Piroxicam gel
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piroxicam gel (0.5% w/w)
Study: 8829026
Drug: Diclofenac gel
Normalized name: diclofenac Topical Gel
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac gel (1% w/w)
Study: 1483069
Drug: Inhaled platelet-activating
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled platelet-activating factor (200 micrograms)
Study: 3912961
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment for TENS
Study: 26015451
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training (four times daily at 60% to 70% of VO2max for four weeks)
Study: 25346155
Drug: OXN PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: OXN PR (combined prolonged-release oxycodone and naloxone)
Study: 25346155
Drug: Oxy PR
Normalized name: Acarboxy prothrombin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxy PR (oxycodone prolonged-release tablets)
Study: 22169699
Drug: Intra-articular hyaluronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular hyaluronic acid (HA) treatment (3 weekly injections of 2 ml of 20 mg/ml HA)
Study: 22169699
Drug: Placebo (P)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (P) (3 weekly injections of 1.2 ml of 0.001 mg/ml HA)
Study: 7853086
Drug: Rectal thermometer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal thermometer
Study: 2697210
Drug: methylprednisolone plus
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: methylprednisolone plus low‐dose cyclosporin A (CyA; median dose 109 mg/m2 per day = 3.4 mg/kg per day after 1 year)
Study: 2697210
Drug: methylprednisolone plus
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: methylprednisolone plus low‐dose cyclosporin A (CyA)
Study: 29870029
Drug: Non-metformin (Control)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-metformin (Control)
Study: 22497697
Drug: Etravirine (ETR)
Normalized name: Etravirine
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Etravirine (ETR) 200mg twice daily (bid)
Study: 17846101
Drug: Brief Problem‐Solving
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief Problem‐Solving Therapy in Home Care (PST‐HC)
Study: 8052342
Drug: Miglitol 200
Normalized name: Miglitol
DrugBank: Miglitol (DB00491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Miglitol 200 mg at bedtime
Study: 31340042
Drug: ChAd155-RSV low
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ChAd155-RSV low dose (5 × 10^9 viral particles)
Study: 26407616
Drug: Sub‐fascial continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub‐fascial continuous local anaesthetic wound infusion (CLAWI) with 0.2% Bupivacaine plus intravenous paracetamol and rescue intravenous morphine
Study: 26407616
Drug: Epidural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bupivacaine (EPI) plus paracetamol and rescue intravenous morphine
Study: 26407616
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine and paracetamol (standard post‐operative analgesia—SAPA)
Study: 15562267
Drug: Methionine load
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine load (100 mg/kg of body weight)
Study: 11473657
Drug: NESP (0.45
Approvals — FDA: no, EMA: no, PMDA: no
Description: NESP (0.45 microg/kg once weekly)
Study: 11473657
Drug: rHuEPO (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO (50 U/kg twice weekly)
Study: 2921077
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (2,160 mg/day)
Study: 26684819
Drug: IL-7 injections
Normalized name: IL-7
DrugBank: Interleukin-7 (DB11997)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-7 injections (3 weekly injections at weeks 8, 9, and 10)
Study: 26684819
Drug: IL-7 injections
Normalized name: IL-7
DrugBank: Interleukin-7 (DB11997)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-7 injections
Study: 26684819
Drug: IL-7 injections
Normalized name: IL-7
DrugBank: Interleukin-7 (DB11997)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-7 injections and dual ART intensification
Study: 22940889
Drug: Intravenous iron(III)‐hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron(III)‐hydroxide sucrose complex, three doses of 100 mg/24 h during pre‐ and postoperative hospitalization and 1 pill/24 h of oral placebo
Study: 22940889
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous fumarate iron 1 pill/24 h pre‐ and postoperatively and during 1 month after discharge, and intravenous placebo while hospitalized